 Trisubstituted naphthylalkylamides for disorders of the melatoninergic system |
| We claim: 1. A compound of formula (I): ##STR28## in which: R represents hydrogen or a radical ... |
|
| Potent inducers of terminal differentiation and method of use thereof |
| OF THE INVENTION The invention provides a class of compounds having the structure: [R--A]--B--A.... |
|
| Production of propionic acid |
| What is claimed is: 1. A one-step process for the preparation of propionic acid which comprises ... |
|
| 1-Ethyl-1-(alkoxycarbonylethyl)-octahydro-indolo[2,3-a]quinolizines |
| What we claim is: 1. 1.alpha.-Ethyl-1-(sec-butoxycarbonyl-ethyl)-1,2,3,4,6,7,12, 12b.alpha.-... |
|
| Saccharase inhibiting 3,4,5-trihydroxypiperidine derivatives |
| What is claimed is: 1. A 3,4,5-trihydroxypiperidine derivative of the formula ##STR99## or a ... |
|
| Substituted hydroxy pyridones |
| What is claimed is: 1. A compound of the formula ##STR8## where R.sub.1 represents lower alkyl or ... |
|
| Methyl 1-(3,4-dichlorobenzyl)-2,3-dioxoisonipecotate |
| What is claimed: 1. Methyl 1-(3,4-dichlorobenzyl)-2,3-dioxoisonipecotate.
Description:
... |
|
| Tetrazolyl containing naphthyridine 3-carboxamides |
| We claim: 1. A compound of the formula ##SPC5## or the formula ##SPC6## in which R.sub.1 represents ... |
|
| Phosphorus-containing squalene synthetase inhibitors, new intermediates and method |
| What is claimed is: 1. A compound having the structure ##STR41## wherein R.sup.5 is OH or Cl and Q ... |
|
| Substituted aminoalkylphosphinic acids |
| We claim: 1. A method of treatment of spinal spasticity, multiple sclerosis, cerebral palsy, ... |
|
|
Treatment of liver dysfunction with 2-amino-6-benzyl-3-ethoxycarbonyl-4,5,6,7-tetrahydro-thieno[2,3-c]pyridi ne hydrochloride
| Details |
Inventors: Kobayakawa, Toshihiro; Yasuda, Hiroshi; Goto, Kazuhiro; Nakanishi, Michio;
Assignee: Yoshitomi Pharmaceutical Industries, Ltd. (Osaka, JA)
Primary Examiner: Meyers; Albert T.
Assistant Examiner: Stephens; Daren M.
Attorney, Agent or Firm: Sughrue, Rothwell, Mion, Zinn & Macpeak
Pharmaceutical compositions containing 2-amino-6-benzyl-3-ethoxycarbonyl-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine hydrochloride and a method of using such compositions in treatment of liver dysfunction in mammals are disclosed. |
|
DETAILED DESCRIPTION OF THE INVENTION The present invention has been accomplished on the basis of new finding that tinoridine hydrochloride shows highly protective effects on liver injuries of animals caused by carbon tetrachloride, thioacetamide and D-galactosamine.
Such excellent pharmacological efforts are recognized as being indicative of effect in humans who are afflicted with liver dysfunction such as acute and chronic hepatitis, liver cirrhosis, fatty liver and toxic hepatitis induced by ethanol, organophosphorus insecticide, chloroform, carbon tetrachloride and so on.
(see, for example, Arzneimittel-Forschung, vol.
18, 698 (1968) and vol.
21, 1194, 1209 (1971)) Protective effects of tinoridine hydrochloride on experimental disturbances in the rat liver are shown below: I.
Methods 1.
Protective effect against acute liver injury by carbon tetrachloride Essentially the test was performed according to the method described by Von G.
Hahn et al.
in "Arzneimittel-Forschung", vol.
18, 698 (1968).
Carbon tetrachloride (CCl.
sub.
4) was dissolved in olive oil and injected intraperitoneally at a dose of 0.
25 ml/kg to male Wistar rats (about 200 g).
Then serum glutamic oxalacetic transaminase (S-GOT) and serum glutamic pyruvic transaminase (S-GPT) were determined by AutoAnalyser AA-II (Technicon Corporation) 24 hours after the CCl.
sub.
4 injection.
The test compound (tinoridine hydrochloride) was administered orally one hour before the CCl.
sub.
4 injection.
The results are shown in Table I.
2.
Protective effect against acute liver injury by thioacetamide The test was also performed essentially according to the method mentioned above.
Thioacetamide was dissolved in water and injected subcutaneously at a dose of 50 mg/kg to male Wistar rats (about 200 g).
Then S-GOT and S-GPT activities were determined by AutoAnalyzer AA-II 24 hours after the thioacetamide injection.
The test compound was administered orally one hour before the thioacetamide injection.
The results are shown in Table II.
3.
Protective effect against acute liver injury by D-galactosamine Essentially the test was performed according to the method described by D
|
|
Vasodialators 
